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Background: Artemisinin-based combination therapy (ACT) has been promoted as a means to reduce malaria
transmission due to their ability to kill both asexual blood stages of malaria parasites, which sustain infections over
long periods and the immature derived sexual stages responsible for infecting mosquitoes and onward
transmission. Early studies reported a temporal association between ACT introduction and reduced malaria
transmission in a number of ecological settings. However, these reports have come from areas with low to
moderate malaria transmission, been confounded by the presence of other interventions or environmental changes
that may have reduced malaria transmission, and have not included a comparison group without ACT. This report
presents results from the first large-scale observational study to assess the impact of case management with ACT on
population-level measures of malaria endemicity in an area with intense transmission where the benefits of effective
infection clearance might be compromised by frequent and repeated re-infection.
Methods: A pre-post observational study with a non-randomized comparison group was conducted at two sites in
Tanzania. Both sites used sulphadoxine-pyrimethamine (SP) monotherapy as a first-line anti-malarial from mid-2001
through 2002. In 2003, the ACT, artesunate (AS) co-administered with SP (AS + SP), was introduced in all fixed health
facilities in the intervention site, including both public and registered non-governmental facilities. Population-level
prevalence of Plasmodium falciparum asexual parasitaemia and gametocytaemia were assessed using light
microscopy from samples collected during representative household surveys in 2001, 2002, 2004, 2005 and 2006.
Findings: Among 37,309 observations included in the analysis, annual asexual parasitaemia prevalence in persons of
all ages ranged from 11% to 28% and gametocytaemia prevalence ranged from <1% to 2% between the two sites
and across the five survey years. A multivariable logistic regression model was fitted to adjust for age, socioeconomic
status, bed net use and rainfall. In the presence of consistently high coverage and efficacy of SP monotherapy and
AS + SP in the comparison and intervention areas, the introduction of ACT in the intervention site was associated
with a modest reduction in the adjusted asexual parasitaemia prevalence of 5 percentage-points or 23%
(p< 0.0001) relative to the comparison site. Gametocytaemia prevalence did not differ significantly (p = 0.30).* Correspondence: rkhatib@ihi.or.tz
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http://www.malariajournal.com/content/11/1/140Interpretation: The introduction of ACT at fixed health facilities only modestly reduced asexual parasitaemia
prevalence. ACT is effective for treatment of uncomplicated malaria and should have substantial public health
impact on morbidity and mortality, but is unlikely to reduce malaria transmission substantially in much of sub-
Saharan Africa where individuals are rapidly re-infected.
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Malaria continues to be a major cause of morbidity and
mortality in sub-Saharan Africa. Vector control interven-
tions and case management continue to be the corner-
stones of malaria control efforts [1,2]. In recent years,
artemisinin-based combination therapy (ACT) has been
introduced for malaria case management in nearly all
countries in sub-Saharan Africa, based mostly on its clin-
ical efficacy at the individual level. However, part of the
promise of ACT-based case management has been the
potential to reduce malaria transmission through the
gametocytocidal effects of ACT [3-8] as well as the post-
treatment prophylactic effect of the partner drug [9]. Al-
though several reports have suggested the impact of
ACT on population-level malaria burden, most have
used a pre-post design without a comparison group, have
failed to account for the influences of concomitant inter-
ventions, such as indoor residual spraying and ecological
changes that may have also reduced transmission, or
have been limited to areas of low malaria transmission
[10-15]. Few studies have been designed to quantify the
independent impact of ACT-based case management
policy on malaria prevalence in areas of high malaria
transmission by incorporating contemporaneous obser-
vational outcomes in areas without the benefit of ACT.
Malaria transmission is dependent on mosquito vector
dynamics, the proportion of humans with peripheral game-
tocytaemia, and the infectiousness of circulating gameto-
cytes to mosquitoes. The relationship between malaria
endemicity, the prevalence of the disease in the population,
and transmission has been defined for moderate to high
transmission settings [16]. Asexual parasitaemia prevalence
continues to be an accepted measure of malaria endemicity
in high transmission settings and is a measureable human
correlate of malaria transmission intensity in the popula-
tion [17]. Unfortunately, more precise human correlates of
transmission intensity, such as incidence, are difficult to
measure in high transmission settings and in studies of
case management interventions. If the introduction of
ACT with its gametocytocidal properties has an impact on
malaria transmission, it should be possible to detect a re-
duction in asexual parasitaemia prevalence following its
widespread uptake.
In 2003, the Interdisciplinary Monitoring Project for Anti-
Malarial Combination Therapy in Tanzania (IMPACT-Tz)assisted the Ministry of Health to implement artesunate
(AS) plus sulphadoxine-pyrimethamine (SP) combination
treatment at all 56 health facilities in Rufiji District as the
first-line treatment for uncomplicated malaria, while the
official first-line anti-malarial was still SP monotherapy in
the rest of Tanzania, having been rolled out nationwide in
August 2001. The primary objective of IMPACT-Tz was to
evaluate the feasibility of delivering ACT through routine
health systems as well as the potential of AS+ SP combin-
ation treatment to prevent the spread of SP drug resist-
ance and reduce malaria transmission [18,19]. In this
paper, the impact of introducing AS+SP in public and
registered non-governmental organization health facilities
on population asexual parasitaemia and gametocytaemia
prevalence is explored. This is the first study to assess the
population-level impact of introducing ACT in an obser-
vational setting with a contemporaneous comparison
group.
Methods
Study site
The study was conducted in two Demographic and
Health Surveillance System (DHSS) sites, Kilombero-
Ulanga DHSS and Rufiji DHSS, in southern Tanzania.
The Kilombero-Ulanga DHSS had 72,000 population
[20] while the Rufiji DHSS had 85,000 population [21].
Both sites are situated in the Greater Rufiji River Basin,
experience perennial malaria transmission, and are pri-
marily rural with the majority of the population relying
on subsistence farming or fishing. Both sites have been
used for other malaria studies; most importantly, the
Kilombero-Ulanga site was used for a study on the social
marketing of ITNs [22] and ITN use was substantially
higher in this site compared to the Rufiji site at the start
of this evaluation in 2001. Social marketing of ITNs,
along with subsidized distribution through a voucher
system in antenatal clinics and supplementary free mass
distribution campaigns, increased coverage of ITNs in
both study sites by 2006 [23-26]. Both sites were used
for the Integrated Management of Childhood Illness
Multi-Country Evaluation with Rufiji serving as an inter-
vention area and Kilombero-Ulanga as the comparison
area [27]. Lastly, the Kilombero-Ulanga DHSS was used
for the ACCESS Programme from 2004 to 2008, a qual-
ity improvement project aimed at enhancing access to
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social marketing for improved care-seeking and quality
of care at health facilities [28-31].
The health system in both sites was comprised of a
network of hospitals, health centers and dispensaries
operated by the government of Tanzania and non-
governmental organizations. Most persons obtained
anti-malarials from health facilities, drug shops or
general shops. Most anti-malarial prescribing was
based on clinical diagnosis alone and few patients
received anti-malarials based on laboratory-confirmed
parasitaemia.Study design
A pre-post observational study with a non-randomized
comparison group was undertaken over six years. Both
sites used SP monotherapy as a first-line anti-malarial
from 2001–2002. According to recommendations of the
National Malaria Control Programme [32], SP mono-
therapy was dispensed in seven age- or weight-specific
dosing bands to achieve a target total sulphadoxine dose
of 25 mg/kg. It was further recommended that SP be
given as a single stat treatment dose under direct obser-
vation in the health facility. In March 2003, the Council
Health Management Team implemented AS+ SP com-
bination therapy as the first-line anti-malarial delivered
through all the fixed health facilities in Rufiji District
alone. As had been done in ACT efficacy studies, AS+
SP was dispensed in four age- and weight-specific dosing
bands to achieve a total target dose of 25 mg/kg sulpha-
doxine stat and 12 mg/kg artesunate divided in 3 daily
doses [33]. The complete dose of SP and the first daily
dose of AS were delivered under direct observation in
the health facility, and the patient was sent home with
remaining doses of AS in preprinted dosing envelopes
[34]. SP monotherapy continued to be the first-line anti-
malarial in Kilombero-Ulanga, the comparison site, as
well as in the rest of the country. Trends in prevalence
of asexual parasitaemia and gametocytaemia were
observed across both sites before and after the introduc-
tion of AS + SP in Rufiji.Implementation of AS+ SP
As part of IMPACT-Tz, World Health Organization
(WHO) prequalified AS tablets (ArsumaxW 50 mg,
Sanofi, Gentilly, France) were supplied to the Rufiji site
and relied on existing systems for the delivery of SP. At
the time, no co-packaged or co-formulated ACT product
was available and SP+AS was co-administered at the
point of care. In addition, all health workers providing
clinical services in Rufiji District were equipped with
training and job-aids to support the ACT use, first in
2003 and again in 2005. AS supply was closelymonitored to minimize stock-outs. Stock-outs were rare
until 2006 when delays in introducing artemether-lume-
fantrine as first-line therapy, originally planned in 2004,
led to shortages of both AS (in Rufiji) and SP (through-
out all of mainland Tanzania).Household survey data collection procedures
Cross-sectional household surveys were completed in
both sites in 2001, 2002, 2004, 2005, and 2006. House-
holds were randomly selected from the two DHSS sites
covering a combined area of 29,000 km2 and including
communities as far as 300 km apart. Independent sam-
ples from the same 56 census enumerated villages (31
in Rufiji and 25 in Kilombero-Ulanga) were selected for
each survey year. All surveys were conducted between
June and September, which coincides with the end of
the long rainy season when malaria is reportedly at its
peak. A standardized questionnaire to measure inter-
nationally recognized indicators [35] was administered
to the head of the household and individual household
members. Study participants were individually asked for
written informed consent. For children less than
12 years old, consent was obtained from the parent or
guardian. A finger prick blood sample was taken from
every member of the household available on the day of
the visit and a blood slide collected. Blood slides were
sent to an Ifakara Health Institute reference laboratory
where they were stained with Giemsa and read by
trained microscopists using standard procedures for
preparation, interpretation and reporting, as described
earlier [36]. Both P. falciparum and non-falciparum
asexual parasites and gametocytes were identified, but
over 98% of malaria infections in these areas were due
to P. falciparum and prevalence of nonfalciparum infec-
tion is not reported. Asexual parasites and gametocytes
were quantified by counting number of parasites per
500 white blood cells. Parasite density was estimated by
assuming a count of 8,000 white blood cells per micro-
litre. Five percent of slides read by each microscopist
were read again by a senior laboratory technician for
quality control; discordant readings were consistently
less than 14%.In vivo study data collection and analysis
Standard in vivo efficacy studies based on 1996 and
2003 WHO protocols [37,38] were also completed in
both Rufiji and Kilombero-Ulanga DHSSs in 2001, 2002,
2004, and 2006. Children <5 years old with documented
fever (axillary temperature >37.5°C) in the absence of
another obvious cause of fever, and mono-infection with
P. falciparum of between 2,000 and 250,000 asexual
parasites/mm3 as determined by microscopic examination
of a peripheral blood smear were enrolled and informed
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reported history of allergy to anti-malarial or sulpha drugs,
were excluded. Patients were randomly allocated to receive
standard doses of either SP or AS+SP [37]. Patients were
followed up on days 1, 2, 3, 7 and 14 in all years. To
standardize analysis across all years and sites, all in vivo
data were analysed using modified 2003 WHO definitions
of clinical and parasitological failure up to day 14 [37], as
well as the 1996 WHO definition of adequate clinical re-
sponse at day 14 [38], which was the prevailing recommen-
dation at the onset of the study. Polymerase chain reaction
correction was not performed until 2004, and those results
are not presented here.
Ethical approval
Ethical approval for the studies was obtained from the
institutional review boards of Ifakara Health Research
and Development Centre (IHRDC, now Ifakara Health
Institute), the United States Centers for Disease Control
and Prevention (CDC), the London School of Hygiene
and Tropical Medicine, and the National Tanzanian
Medical Research Co-ordinating Committee of the Na-
tional Institute for Medical Research.
Data analysis
Data were double entered using Microsoft FoxPro soft-
ware (Redmond, Washington, United States) and ana-
lysed using SAS version 9.2 (SAS Institute, Cary, North
Carolina, United States). Descriptive analyses were done
using the survey analysis tools, which use the Taylor ex-
pansion method to account for household-level cluster-
ing. Comparisons of proportions were done using the
Wald chi square. Univariate and multivariate logistic re-
gression modelling were performed using the surveylo-
gistic procedure. Statistical significance was defined as a
p-value ≤0.05. An index of socio-economic status was
generated for each survey year separately using principal
components analysis for household characteristics and
asset ownership as described elsewhere [39]. Monthly
rainfall data were collected from weather stations adja-
cent to the respective DHSS sites. A conservative esti-
mate of the annual population drug pressure defined as
the number of anti-malarial treatments per 100 persons
per year was calculated by multiplying the proportion of
persons who reported receiving an anti-malarial during
the two week recall period of the survey by 26, the num-
ber of two-week periods per year. This estimate assumes
constant anti-malarial use throughout the year.
Multivariate logistic regression was used to assess the
effect of implementation of AS + SP on asexual parasit-
aemia and gametocytaemia. Using a model with terms
for study group (intervention versus comparison), survey
year, and intervention (implementation of AS + SP in
Rufiji in 2004–2006), changes in asexual parasitaemiaand gametocytaemia prevalence were compared between
the pre-intervention and post-intervention surveys, as
well as changes in their relative difference (i.e. change in
the intervention group between pre- and post-surveys
versus change in the comparison group). The model was
adjusted for potential confounding by including age
group, untreated bed net and ITN use, socioeconomic
status, and rainfall in the six months prior to interview.
Role of funding source
The sponsor of the study had no role in study design,
data collection, data analysis, data interpretation, or writ-
ing of the report. The corresponding author had full ac-
cess to all of the data in the study and had final
responsibility for the decision to submit for publication.
Results
The surveys included 38,872 persons; but analysis is lim-
ited to the 37,309 (96%) persons for whom complete data
were available. The age and socioeconomic status distri-
butions were similar across sites and years (Table 1).
However, use of untreated bed nets and ITNs was con-
sistently higher in Kilombero-Ulanga than Rufiji. Mean
rainfall varied from year to year and was often higher in
Kilombero-Ulanga compared to Rufiji.
The prevalence of fever varied significantly by year and
site with a range of 9 to 20% reporting fever in the prior
two weeks. About 3–5% of the entire population was
treated with any anti-malarial for an episode of fever in
the prior two weeks and the estimated annual drug pres-
sure varied between 73 and 162 anti-malarial treatments
per 100 persons per year. In Rufiji in 2004–2006, the an-
nual population drug pressure using AS+ SP varied from
20 to 87 AS+ SP treatments per 100 persons per year.
AS+ SP delivered through public and non-governmental
organization health facilities accounted for 27% to 67%
of all anti-malarial treatments reported by persons with a
febrile illness in the prior two weeks in Rufiji from
2004–2006. SP and AS+ SP efficacy was assessed using
modified in vivo studies. Both anti-malarial regimens
were efficacious in 2001 with an adequate clinical and
parasitological response at day 14 (ACPR) of 91% for SP
and 97–100% for AS+ SP. SP monotherapy was noted to
have declining efficacy with an ACPR of 65–86% in 2004
and 2006 and had moderate levels of adequate clinical
response (77%–92%) as it had been defined in 1996
(Table 2). AS + SP continued to be highly efficacious with
an ACPR of 89–100% in 2004 and 2006.
Asexual parasitaemia prevalence varied from 11 to 28%
(Table 1) and decreased from 23% to 14% (−9%-points)
in Rufiji between 2001–2002 and 2004–2006, and from
18% to 14% (−4%-points) in Kilombero-Ulanga between
2001–2002 and 2004–2006, respectively. The change in
intervention site minus the change in the comparison
Table 1 Characteristics of study populations in Rufiji and Kilombero-Ulanga (KU) Demographic and Health Surveillance System sites, Tanzania, 2001, 2002,
2004, 2005, 2006 (N=37,309)
2001 2002 2004 2005 2006
Rufiji
(N =1,521)
n (%)
KU
(N=1,543)
n (%)
Rufiji
(N = 2,956)
n (%)
KU
(N=3,885)
n (%)
Rufiji
(N= 3,715)
n (%)
KU
(N=4,044)
n (%)
Rufiji
(N= 5,399)
n (%)
KU
(N=4,902)
n (%)
Rufiji
(N =4,190)
n (%)
KU
(N=5,223)
n (%)
Median age in years (interquartile range) 16 (6–39) 19 (7–35) 15 (6–36) 17 (6–34) 14 (5–35) 15 (5–35) 14 (5–35) 15 (5–33) 14 (5–34) 15 (6–34)
Age groups
<1 year old 38 (2%) 44 (3%) 81 (3%) 95 (2%) 100 (3%) 156 (4%) 128 (2%) 207 (4%) 157 (4%) 163 (3%)
1–4 years old 229 (15%) 209 (14%) 453 (15%) 628 (16%) 639 (17%) 652 (16%) 957 (18%) 820 (17%) 675 (16%) 781 (15%)
5–15 years old 466 (31%) 432 (28%) 929 (31%) 1115 (29%) 1180 (32%) 1201 (30%) 1717 (32%) 1473 (30%) 1369 (33%) 1629 (31%)
>15 years old 788 (52%) 858 (56%) 1493 (51%) 2035 (53%) 1796 (48%) 2035 (50%) 2597 (48%) 2402 (49%) 1989 (47%) 2618 (50%)
Bed net use previous night
Used untreated net 235 (15%) 911 (59%) 437 (15%) 2312 (60%) 416 (11%) 2063 (51%) 911 (17%) 2302 (47%) 1430 (34%) 2640 (51%)
Uses insecticide treated net 42 (3%) 145 (9%) 70 (2%) 395 (10%) 370 (10%) 1045 (26%) 1197 (22%) 1688 (34%) 1300 (31%) 1864 (36%)
Socioeconomic status by asset index
Poorest 287 (19%) 394 (26%) 410 (17%) 629 (17%) 625 (17%) 787 (19%) 853 (16%) 844 (17%) 593 (14%) 942 (18%)
Less poor 163 (11%) 224 (15%) 337 (14%) 715 (19%) 823 (22%) 624 (15%) 1074 (20%) 1004 (20%) 816 (19%) 998 (19%)
Middle 281 (18%) 332 (22%) 496 (20%) 804 (21%) 805 (22%) 766 (19%) 1159 (21%) 958 (20%) 938 (22%) 1048 (20%)
More rich 416 (27%) 249 (16%) 589 (24%) 830 (22%) 726 (20%) 984 (24%) 1224 (23%) 977 (20%) 903 (22%) 1125 (22%)
Least poor 374 (25%) 344 (22%) 613 (25%) 799 (21%) 736 (20%) 883 (22%) 1089 (20%) 1119 (23%) 940 (22%) 1079 (21%)
Mean rainfall in previous 6 months
from date of interview (in cm)
61.3 44.2 96.4 198.4 74.5 149.0 67.6 146.1 93.3 136.1
Malaria burden
Asexual parasitaemia 400 (26%) 274 (18%) 828 (28%) 851 (22%) 696 (19%) 1013 (25%) 999 (19%) 559 (11%) 633 (15%) 698 (13%)
Geometric mean asexual
parasite density (95% CL)
886
(746,1052)
1008
(830,1222)
821
(736,916)
1032
(923,1152)
1104
(969,1259)
992
(895,1100)
1122
(1008,1248)
727
(637,831)
2144
(1837,2504)
540
(482,605)
Gametocytaemia 30 (2%) 23 (1%) 44 (1%) 69 (2%) 23 (1%) 73 (2%) 47 (1%) 14 (<1%) 14 (<1%) 25 (<1%)
Geometric mean gametocyte
density (95% CL)
66(50,86) 113 (69,186) 104 (60,183) 97(76,123) 76(46,125) 91(74,113) 67(46,99) 67(38,121) 224 (95,528) 128 (48,343)
Gametocytemic patients
of parasitemic pts
30/400 (7.5%) 23/274 (8.4%) 44/828 (5.3%) 69/851 (8.1%) 23/696 (3.3%) 73/1013 (7.2%) 47/999(4.7%) 14/559 (2.5%) 14/633 (2.2%) 25/698 (3.6%)
Fever in prior two weeks 301 (20%) 227 (15%) 339 (11%) 571 (15%) 377 (10%) 421 (10%) 756 (14%) 484 (10%) 457 (11%) 462 (9%)
Health seeking and anti-malarial
use for febrile illness in prior two weeks
Use of health facility 89 (6%) 57 (4%) 115 (4%) 187 (5%) 160 (4%) 107 (3%) 299 (6%) 163 (3%) 130 (3%) 193 (4%)
Use of any anti-malarial 69 (5%) 78 (5%) 98 (3%) 242 (6%) 152 (4%) 212 (5%) 270 (5%) 267 (5%) 117 (3%) 287 (6%)
Use of sulphadoxine-pyrimethamine only 25 (2%) 6 (<1%) 65 (2%) 144 (4%) 41 (1%) 104 (3%) 36 (1%) 120 (2%) 42 (1%) 136 (3%)
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Table 1 Characteristics of study populations in Rufiji and Kilombero-Ulanga (KU) Demographic and Health Surveillance System sites, Tanzania, 2001, 2002,
2004, 2005, 2006 (N=37,309) (Continued)
Use of artesunate-sulphadoxine-pyrimethamine 0 (0%) 0 (0%) 0 (0%) 0 (0%) 83 (2%) 0 (0%) 180 (3%) 0 (0%) 32 (1%) 0 (0%)
Use of artesunate monotherapy 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (<1%) 0 (0%) 5 (<1%) 0 (0%) 10 (<1%) 0 (0%)
Use of other anti-malarial* 44 (3%) 72 (5%) 33 (1%) 98 (3%) 27 (1%) 108 (3%) 52 (1%) 147 (3%) 33 (1%) 151 (3%)
Estimated number of anti-malarial
treatments per 100 persons per year†
Any anti-malarial 118 131 86 162 106 136 130 142 73 143
Sulphadoxine-pyrimethamine only 43 10 57 96 29 67 17 64 26 68
Artesunate-sulphadoxine-pyrimethamine 0 0 0 0 58 0 87 0 20 0
Other anti-malarial* 75 121 29 66 19 69 25 80 20 75
*Primarily quinine, amodiaquine and very rarely chloroquine.
† An estimate of the annual population drug pressure defined as the number of anti-malarial treatments per 100 persons per year was calculated by multiplying the proportion of persons receiving an anti-malarial
during the two week recall period of the survey by 26 (the number of 2 week periods per year).
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Table 2 In vivo efficacy of sulphadoxine-pyrimethamine (SP) and artesunate-sulphadoxine-pyrimethamine (AS+ SP) for the treatment of uncomplicated malaria
in children <5 years old in Rufiji and Kilombero-Ulanga (KU) Demographic and Health Surveillance System sites, Tanzania, 2001, 2002, 2004, 2006
2001 2002 2004 2006
Rufiji KU Rufiji KU Rufiji KU Rufiji KU
Sulphadoxine-pyrimethamine (N=74) (N=66) (N=87) (N=77) (N= 66) (N= 65) (N= 57) (N= 52)
Early treatment failure (ETF)1 0% 5% 6% 0% 11% 5% 4% 13%
Late treatment failure
Late clinical failure (LCF)2 1% 0% 0% 0% 8% 3% 19% 10%
Late parasitological failure (LPF)3 8% 5% 18% 8% 5% 6% 7% 12%
Adequate Clinical Response (ACR) 99% 95% 94% 100% 82% 92% 77% 77%
Adequate Clinical and Parasitological
Response (ACPR)4 at Day 14
91% 91% 76% 92% 77% 86% 70% 65%
Artesunate-sulphadoxine-pyrimethamine (N=67) (N=59) (N=86) (N=78) (N= 72) (N= 66) (N= 58) (N= 57)
Early treatment failure (ETF)1 0% 0% 5% 0% 0% 0% 0% 0%
Late treatment failure
Late clinical failure (LCF)2 0% 0% 0% 0% 0% 0% 5% 7%
Late parasitological failure (LPF)3 0% 3% 9% 4% 3% 0% 2% 4%
Adequate Clinical Response (ACR) 100% 100% 95% 100% 100% 100% 95% 93%
Adequate Clinical and Parasitological
Response (ACPR)4 at Day 14
100% 97% 86% 96% 97% 100% 93% 89%
1 Early treatment failure defined as: development of danger signs or severe malaria on day 1, day 2 or day 3 in the presence of parasitaemia; or parasitaemia on day 2 higher than day 0 count irrespective of axillary
temperature; or parasitaemia on day 3 with axillary temperature ≥37.5°C; or parasitaemia on day 3 ≥25% of count on day 0.
2 Late clinical failure defined as development of danger signs or severe malaria on any day from day 4 to day 28 in the presence of parasitaemia, without previously meeting any of the criteria of Early Treatment
Failure; or presence of parasitaemia and axillary temperature ≥37.5°C on any day from day 4 to day 14, without previously meeting any of the criteria of Early Treatment Failure.
3 Late parasitological failure defined as presence of parasitaemia on any day from day 7 to day 14 and axillary temperature <37.5°C, without previously meeting any of the criteria of Early Treatment Failure or Late
Clinical Failure.
4 Adequate clinical and parasitological response at day 14 defined absence of parasitaemia on day 14 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late
Clinical Failure or Late Parasitological Failure.
Note: In 2001, 4 patients were lost to follow-up from Rufiji with 2 in the SP group and 2 in the AS + SP group, while 7 patients were lost in KU with 4 in the SP group and 3 in the AS + SP group. In 2004, 12 patients
were lost in Rufiji with 9 in the SP group and 3 in the AS + SP group; 5 were lost in KU with 3 in the SP group and 2 in the AS + SP group. In 2006, 5 patients were lost to follow-up in Rufiji with 2 in the SP group and 3
in the AS + SP group; 14 were lost in KU with 10 in the SP group and 4 in the AS + SP group.
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http://www.malariajournal.com/content/11/1/140site was −5 percentage-points or −23%. Using a logistic
regression model with terms for site, survey year and inter-
vention (i.e. Rufiji in 2004–2006), age group, socioeconomic
status, untreated bed net and ITN use, and rainfall in the
six months before the interview date, the implementation
of AS+SP was associated with a net decrease in asexual
parasitaemia prevalence of 5 percentage-points or a relative
decrease of 23% (Table 3, Figure 1). Gametocytaemia preva-
lence was low, ranging from <1% to 2%, and was not
significantly associated with the implementation of AS+SP
in Rufiji (p=0.30) (Table 1, Table 4).
Discussion
Artemisinin-based combination therapy has been adopted
as first-line anti-malarials for case management by most
malaria-endemic countries. The change to ACT in most
cases was prompted by the development of resistance to
conventional anti-malarial monotherapies creating theTable 3 Predictors of asexual parasitaemia in Rufiji and Kilom
System sites, Tanzania, 2001, 2002, 2004, 2005, 2006 (N=37,
Variable Estim
Year of survey
2001 Refe
2002 0.14
2004 0.09
2005 −0.3
2006 −0.4
Demographic and health surveillance system site
KU Refe
Rufiji 0.30
Implementation of artesunate-sulphadoxine-pyrimethamine −0.3
Age group
<1 0.88
1-< 5 years 1.70
5–15 years 1.59
>15 years Refe
Bed net use previous night
No net use Refe
Used untreated net −0.2
Uses insecticide treated net −0.2
Wealth quintile
Poorest 0.53
Less poor 0.48
Middle 0.48
More rich 0.34
Least poor Refe
Rainfall
Rainfall in the 6 months before interview (per cm) 0.000need to implement a clinically efficacious drug and sup-
ported by the potential for reduced transmission and
delayed development or spread of anti-malarial drug resist-
ance. However, little is still known about the impact of
introducing ACT on malaria endemicity as measured by
asexual parasitaemia prevalence, especially in settings of
high malaria transmission. The results of this large obser-
vational study document that implementation of AS+ SP
was associated with a modest decrease in the population
asexual parasitaemia prevalence.
This evaluation design with a contemporaneous com-
parison group, allows adjustment for potential confoun-
ders, such as untreated net and ITN use, rainfall, and
other factors that are associated with parasitaemia, such
as age and socioeconomic status. Prior studies have
demonstrated individual level clinical efficacy of ACT
and some studies have suggested reduced malaria burden
with ACT implementation [10-14], but to date there hasbero-Ulanga (KU) Demographic and Health Surveillance
309)
ate p-value Adjusted odds ratio (95% confidence interval)
rent Referent Referent
57 0.0966 1.157 (0.974–1.374)
78 0.2319 1.103 (0.939–1.294)
882 <0.0001 0.678 (0.480–0.793)
058 <0.0001 0.666 (0.566–0.785)
rent Referent Referent
92 <0.0001 1.362 (1.174–1.580)
366 <0.0001 0.714 (0.619–0.823)
73 <0.0001 2.428 (2.059–2.864)
99 <0.0001 5.529 (5.106–5.986)
28 <0.0001 4.918 (4.580–5.280)
rent Referent Referent
rent Referent Referent
893 <0.0001 0.749 (0.689–0.814)
590 <0.0001 0.772 (0.696–0.856)
31 <0.0001 1.704 (1.520–1.911)
62 <0.0001 1.626 (1.453–1.820)
16 <0.0001 1.619 (1.453–1.804)
36 <0.0001 1.410 (1.266–1.571)
rent Referent Referent
272 0.6653 1.000 (0.999–1.002)
Figure 1 Measured (a) and modeled (b) asexual parasitaemia prevalence in Rufiji and Kilombero-Ulanga (KU) Demographic and Health
Surveillance System (DHSS) sites, Tanzania, 2001, 2002, 2004, 2005, 2006 (N=37,309).
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http://www.malariajournal.com/content/11/1/140been little evidence for the independent contribution of
ACT-based case management over and above vector
control interventions. This study is the first to show an
independent association between ACT implementation
and malaria endemicity after controlling for other mal-
aria interventions such as ITN use, environmental fac-
tors such as rainfall, and other secular trends.
These findings suggest it is plausible that the introduc-
tion of AS+SP contributed to the reduction in asexual
parasitaemia prevalence is based on an ecological associ-
ation between the introduction of AS+SP and decreased
asexual parasitaemia prevalence. After implementation of
AS+SP, 20 to 87 AS+SP treatments per 100 persons per
year were delivered through fixed health facilities. Al-
though this number varied substantially during the study
time period and is based on individual recall and anunderlying assumption that AS+ SP use was constant
throughout the year, it still represents substantial drug
pressure on the population and could plausibly account
for the decrease in parasitaemia prevalence. Indeed, the
introduction of SP monotherapy at fixed health facilities in
these sites between 2001 and 2002 exerted enough drug
pressure to select for genotypes associated with clinical
drug resistance [40]. A more detailed analysis of dispensing
patterns in Rufiji, Kilombero and Ulanga Districts docu-
menting over 271,953 clinician-patient encounters at
health facilities supports the widespread use of AS+SP in
our intervention site throughout the year [41]. In addition,
AS+SP is likely more efficacious at clearing parasitaemia
than SP alone based on in vivo results collected from these
sites over the same time period as well as published
reports from elsewhere in Tanzania [42-46].
Table 4 Predictors of gametocytaemia in Rufiji and Kilombero-Ulanga (KU) Demographic and Health Surveillance
System sites, Tanzania, 2001, 2002, 2004, 2005, 2006 (N=37,309)
Variable Estimate p-value Adjusted odds ratio (95% confidence interval)
Year of survey
2001 Referent Referent Referent
2002 0.0364 0.8929 1.037 (0.610–1.763)
2004 −0.2546 0.2988 0.775 (0.480–1.253)
2005 −0.9695 <0.0001 0.379 (0.238–0.604)
2006 −1.2736 <0.0001 0.280 (0.165–0.476)
Demographic and health surveillance system site
KU Referent Referent Referent
Rufiji −0.1957 0.3763 0.822 (0.533–1.268)
Implementation of artesunate-sulphadoxine-pyrimethamine −0.2334 0.2961 0.792 (0.511–1.227)
Age group
<1 1.7143 <0.0001 5.553 (3.376–9.133)
1-< 5 years 2.0611 <0.0001 7.854 (5.886–10.481)
5–15 years 1.0336 <0.0001 2.811 (2.061–3.834)
>15 years Referent Referent Referent
Bed net use previous night
No net use Referent Referent Referent
Used untreated net −0.2650 0.0732 0.767 (0.574–1.025)
Uses insecticide treated net −0.2774 0.1478 0.758 (0.520–1.103)
Wealth quintile
Poorest 0.6146 0.0013 1.849 (1.270–2.691)
Less poor 0.3059 0.1289 1.358 (0.915–2.015)
Middle 0.5591 0.0020 1.749 (1.227–2.494)
More rich 0.3651 0.0434 1.441 (1.011–2.053)
Least poor Referent Referent Referent
Rainfall
Rainfall in the 6 months before interview (per cm) −0.00075 0.6850 0.999 (0.996–1.003)
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prevalence of 5 percentage-points or a relative decrease of
23% occurred following the introduction of ACT in Rufiji.
Since asexual parasitaemia prevalence was observed in all
ages and the majority of parasitaemic persons were asymp-
tomatic adults, this finding reflects the effect of ACT on
asymptomatic carriage of parasites mostly in adults. The
relationship between asexual parasitaemia prevalence and
other disease burden estimates, such as uncomplicated or
severe malaria incidence and mortality, is not addressed in
this study. Previous mathematical models suggest an
appreciable reduction in uncomplicated malaria incidence
with the introduction of ACT, thus although the true mag-
nitude of the reduction in malaria morbidity and mortality
that might have been associated with this intervention can-
not be quantified, the modest reduction in malaria endem-
icity noted in this study does not undermine the large
public health impact of ACT.Although a modest reduction in malaria endemicity was
demonstrated, several mechanisms by which the introduc-
tion of ACT might reduce population level asexual parasit-
aemia prevalence are possible. The effect on population
level parasitaemia prevalence might be related to the
ACT’s superior efficacy at the individual level alone. In
addition, the gametocytocidal effects of artemisinins could
contribute, as has been suggested by individual-level stud-
ies [3-8,47,48]. It was not possible to support this claim
with the population-level gametocytaemia prevalence
reported here, as the data were limited by sample size and
the low prevalence (~1%) of gametocytaemia among
asymptomatic community members. Moreover, in this
area of high transmission intensity and frequent AS+SP
use, the decrease in population level parasitaemia might be
due to the post-treatment prophylactic effect of SP. How-
ever, since both sites used SP, it is unlikely that the prophy-
lactic effect would contribute to reduced parasitaemia
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http://www.malariajournal.com/content/11/1/140prevalence differentially in Rufiji versus Kilombero-Ulanga.
Lastly, mathematical models suggest that the introduction
of even highly gametocytocidal ACT for case management
of symptomatic patients with uncomplicated malaria will
have only a modest impact on malaria endemicity, because
of the presence of a large reservoir of asymptomatic
patients who can sustain high levels of transmission and
the rapid re-infection of patients who had been recently
treated with ACT. In addition, the gametocytocidal prop-
erties of artemisinin drugs appear limited to immature sex-
ual stages and mature gametocytes present at the time of
treatment may persist and perpetuate transmission even
after successfully completing an ACT regimen [49]. In
sum, although one or more of several possible mechanisms
may contribute, the modest reduction in parasitaemia
prevalence found in this study is in line with reductions
predicted by mathematical models of case management
using effective artemisinins with rapid schizonticidal activ-
ity, gametocytocidal properties and post-treatment prophy-
lactic effect [9].
Limitations
This study had a number of limitations. The observa-
tional nature of this study leaves the analysis unable to
control or even measure all potential confounders. On
the other hand, the presence of a contemporaneous
comparison area did allow consideration of known en-
vironmental factors such as rainfall and the use of mal-
aria control interventions such as ITNs. Although
randomization and blinding were not practical, the sites
are ecologically similar and were observed over a period
of several years. Prior research in both sites suggests
similar malaria transmission intensity, although differ-
ences in malaria intervention coverage were present as
noted. In addition, the quantification of SP monotherapy
and AS + SP drug pressure may be imprecise as it relied
on individual recall and the assumption that anti-malar-
ial access, uptake and use were constant throughout the
year while the survey was conducted following peak
malaria transmission season each year. In particular,
AS + SP use was likely underestimated for Rufiji in 2006
since the site experienced a localized stockout of AS at
the time of the survey, following delayed implementa-
tion of the National Malaria Control Programme’s plans
to transition to artemether-lumefantrine as a first-line
anti-malarial. However, even rough estimates suggest sub-
stantial AS+ SP drug pressure on the population and sug-
gest it is plausible that the implementation of AS+ SP
contributed to the reduction in parasitaemia prevalence.
Lastly, we relied solely on light microscopy to measure
gametocytaemia, which most likely yields lower preva-
lence than could be detected via newer means such as
molecular assays [50]. This robust data set with obser-
vations over five years using a pre-post evaluationdesign with a non-randomized contemporaneous com-
parison design may offer one of the best opportunities
to observe the impact of ACT policy in a real-world
context. Given the increased use of ACT worldwide it is
unlikely that there will be another such opportunity to
compare ACT and non-ACT case management policies
on such a scale.
Conclusions
A large observational study was used to assess the im-
pact of introducing ACT on population-level malaria
parasitaemia prevalence. This study quantifies the contri-
bution of ACT-based case management policies in redu-
cing malaria endemicity. Many countries in sub-Saharan
Africa have implemented ACT, based on clinical efficacy
alone and the promise of decreased transmission and
reduced risk of developing resistance. This evaluation
sought to measure the impact of such a policy change on
malaria endemicity in a typical health system facing high
levels of malaria transmission. Findings reported here
provide the strongest evidence to date that case manage-
ment with ACT can have a modest independent impact
on malaria endemicity, but is unlikely to markedly re-
duce malaria transmission in high transmission settings
such as most of sub-Saharan Africa.
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